Dr Nicholas Marston, Brigham and Women’s Hospital, Boston, USA
Novel therapies for hypertriglyceridaemia (HTG) reached some major milestones in 2025 including impressive clinical trial results across the three targets for these emerging treatments – ANGPTL3, ANGPTL4 and apoC3 – and the first regulatory approvals for apoC3 inhibitors in patients with familial chylomicronaemia syndrome (FCS). Just as exciting are expectations for 2026, as studies of apoC3-targeting agents continue down the HTG pyramid of severity and ANGPTL3 and ANGPTL4-targeting agents advance from early into later phase clinical trials.
